ALIGOS THERAPEUTICS INC's ticker is ALGS and the CUSIP is 01626L105. A total of 52 filers reported holding ALIGOS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $23,443 | -23.1% | 31,383 | 0.0% | 0.00% | – |
Q2 2023 | $30,473 | -66.1% | 31,383 | -57.6% | 0.00% | – |
Q2 2022 | $90,000 | -66.3% | 73,986 | -40.3% | 0.00% | – |
Q1 2022 | $267,000 | -83.8% | 123,831 | -11.0% | 0.00% | – |
Q4 2021 | $1,651,000 | -21.3% | 139,074 | +2.8% | 0.00% | -100.0% |
Q3 2021 | $2,099,000 | +15.6% | 135,330 | +52.0% | 0.00% | 0.0% |
Q2 2021 | $1,816,000 | +11.5% | 89,039 | +24.4% | 0.00% | 0.0% |
Q1 2021 | $1,629,000 | -8.7% | 71,595 | +11.0% | 0.00% | 0.0% |
Q4 2020 | $1,784,000 | – | 64,514 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 2,320,381 | $1,733,325 | 0.92% |
TANG CAPITAL MANAGEMENT LLC | 3,329,048 | $2,486,799 | 0.35% |
Vivo Capital, LLC | 3,547,030 | $2,649,631 | 0.29% |
Pivotal bioVenture Partners Investment Advisor LLC | 743,215 | $555,182 | 0.22% |
Newtyn Management, LLC | 920,000 | $687,240 | 0.17% |
SILVERARC CAPITAL MANAGEMENT, LLC | 631,887 | $472,020 | 0.14% |
EcoR1 Capital, LLC | 3,948,360 | $2,949,425 | 0.10% |
HHLR ADVISORS, LTD. | 2,309,764 | $1,725,394 | 0.04% |
Baker Brothers Advisors | 2,076,400 | $1,551,071 | 0.01% |
HARBOURVEST PARTNERS LLC | 18,783 | $14,031 | 0.01% |